285 related articles for article (PubMed ID: 16400244)
1. Beyond monoamines: glutamatergic function in mood disorders.
Kugaya A; Sanacora G
CNS Spectr; 2005 Oct; 10(10):808-19. PubMed ID: 16400244
[TBL] [Abstract][Full Text] [Related]
2. The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders.
Machado-Vieira R; Manji HK; Zarate CA
Neuroscientist; 2009 Oct; 15(5):525-39. PubMed ID: 19471044
[TBL] [Abstract][Full Text] [Related]
3. Glutamatergic modulators: the future of treating mood disorders?
Zarate C; Machado-Vieira R; Henter I; Ibrahim L; Diazgranados N; Salvadore G
Harv Rev Psychiatry; 2010; 18(5):293-303. PubMed ID: 20825266
[TBL] [Abstract][Full Text] [Related]
4. [The role of the glutamatergic system in pathophysiology and pharmacotherapy for depression: preclinical and clinical data].
Paslakis G; Gass P; Deuschle M
Fortschr Neurol Psychiatr; 2011 Apr; 79(4):204-12. PubMed ID: 21117011
[TBL] [Abstract][Full Text] [Related]
5. Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status.
Henter ID; Park LT; Zarate CA
CNS Drugs; 2021 May; 35(5):527-543. PubMed ID: 33904154
[TBL] [Abstract][Full Text] [Related]
6. The role of glutamate on the action of antidepressants.
Hashimoto K
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Aug; 35(7):1558-68. PubMed ID: 20600468
[TBL] [Abstract][Full Text] [Related]
7. Glutamatergic approaches in major depressive disorder: focus on ketamine, memantine and riluzole.
Owen RT
Drugs Today (Barc); 2012 Jul; 48(7):469-78. PubMed ID: 22844658
[TBL] [Abstract][Full Text] [Related]
8. Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole.
Banasr M; Chowdhury GM; Terwilliger R; Newton SS; Duman RS; Behar KL; Sanacora G
Mol Psychiatry; 2010 May; 15(5):501-11. PubMed ID: 18825147
[TBL] [Abstract][Full Text] [Related]
9. Employing pharmacologic treatment of bipolar disorder to greatest effect.
Schatzberg AF
J Clin Psychiatry; 2004; 65 Suppl 15():15-20. PubMed ID: 15554791
[TBL] [Abstract][Full Text] [Related]
10. An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression.
Zarate CA; Quiroz JA; Singh JB; Denicoff KD; De Jesus G; Luckenbaugh DA; Charney DS; Manji HK
Biol Psychiatry; 2005 Feb; 57(4):430-2. PubMed ID: 15705360
[TBL] [Abstract][Full Text] [Related]
11. The anticonvulsant lamotrigine in treatment-resistant manic-depressive illness.
Sporn J; Sachs G
J Clin Psychopharmacol; 1997 Jun; 17(3):185-9. PubMed ID: 9169963
[TBL] [Abstract][Full Text] [Related]
12. The current understanding of lamotrigine as a mood stabilizer.
Hahn CG; Gyulai L; Baldassano CF; Lenox RH
J Clin Psychiatry; 2004 Jun; 65(6):791-804. PubMed ID: 15291656
[TBL] [Abstract][Full Text] [Related]
13. Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms.
Sanacora G; Kendell SF; Levin Y; Simen AA; Fenton LR; Coric V; Krystal JH
Biol Psychiatry; 2007 Mar; 61(6):822-5. PubMed ID: 17141740
[TBL] [Abstract][Full Text] [Related]
14. Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments.
Krystal JH; Sanacora G; Blumberg H; Anand A; Charney DS; Marek G; Epperson CN; Goddard A; Mason GF
Mol Psychiatry; 2002; 7 Suppl 1():S71-80. PubMed ID: 11986998
[TBL] [Abstract][Full Text] [Related]
15. The role of NMDA receptors in the pathophysiology and treatment of mood disorders.
Ghasemi M; Phillips C; Trillo L; De Miguel Z; Das D; Salehi A
Neurosci Biobehav Rev; 2014 Nov; 47():336-58. PubMed ID: 25218759
[TBL] [Abstract][Full Text] [Related]
16. Targeting glial physiology and glutamate cycling in the treatment of depression.
Valentine GW; Sanacora G
Biochem Pharmacol; 2009 Sep; 78(5):431-9. PubMed ID: 19376090
[TBL] [Abstract][Full Text] [Related]
17. Novel glutamatergic drugs for the treatment of mood disorders.
Lapidus KA; Soleimani L; Murrough JW
Neuropsychiatr Dis Treat; 2013; 9():1101-12. PubMed ID: 23976856
[TBL] [Abstract][Full Text] [Related]
18. Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder.
Niciu MJ; Ionescu DF; Richards EM; Zarate CA
J Neural Transm (Vienna); 2014 Aug; 121(8):907-24. PubMed ID: 24318540
[TBL] [Abstract][Full Text] [Related]
19. Novel glutamatergic agents for major depressive disorder and bipolar disorder.
Machado-Vieira R; Ibrahim L; Henter ID; Zarate CA
Pharmacol Biochem Behav; 2012 Feb; 100(4):678-87. PubMed ID: 21971560
[TBL] [Abstract][Full Text] [Related]
20. Riluzole in the treatment of mood and anxiety disorders.
Pittenger C; Coric V; Banasr M; Bloch M; Krystal JH; Sanacora G
CNS Drugs; 2008; 22(9):761-86. PubMed ID: 18698875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
